Table of Contents Author Guidelines Submit a Manuscript
Cellular Oncology
Volume 30 (2008), Issue 4, Pages 299-306

Hypermethylation of the FANCC and FANCL Promoter Regions in Sporadic Acute Leukaemia

C. J. Hess,1 N. Ameziane,2 G. J. Schuurhuis,1 A. Errami,3 F. Denkers,1 G. J. L. Kaspers,4,6 J. Cloos,4 H. Joenje,2 D. Reinhardt,5 G. J. Ossenkoppele,1 C. M. Zwaan,6,7 and Q. Waisfisz1

1Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
2Department of Clinical and Human Genetics, VU University Medical Center, Amsterdam, The Netherlands
3MRC-Holland BV, Amsterdam, The Netherlands
4Pediatric Hematology/Oncology, VU University Medical Center, Amsterdam, The Netherlands
5AML-BFM Study Group, Hannover, Germany
6Dutch Childhood Oncology Group, Den Haag, The Netherlands
7Department of Pediatric Oncology, Erasmus Medical Center/Sophia Children’s Hospital, Rotterdam, The Netherlands

Copyright © 2008 Hindawi Publishing Corporation and the authors. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective: Inactivation of the FA-BRCA pathway results in chromosomal instability. Fanconi anaemia (FA) patients have an inherited defect in this pathway and are strongly predisposed to the development of acute myeloid leukaemia (AML). Studies in sporadic cancers have shown promoter methylation of the FANCF gene in a significant proportion of various solid tumours. However, only a single leukaemic case with methylation of one of the FA-BRCA genes has been described to date, i.e. methylation of FANCF in cell line CHRF-288. We investigated the presence of aberrant methylation in 11 FA-BRCA genes in sporadic cases of leukaemia.

Methods: We analyzed promoter methylation in 143 AML bone marrow samples and 97 acute lymphoblastic leukaemia (ALL) samples using methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA). Samples with aberrant methylation were further analyzed by bisulphite sequencing and tested for mitomycin C sensitivity using Colony Forming Units assays.

Results: MS-MLPA showed promoter methylation of FANCC in one AML and three ALL samples, while FANCL was found methylated in one ALL sample. Bisulphite sequencing of promoter regions confirmed hypermethylation in all cases. In addition, samples with hypermethylation of either FANCC or FANCL appeared more sensitive towards mitomycin C in Colony Forming Units assays, compared to controls.

Conclusion: Hypermethylation of promoter regions from FA-BRCA genes does occur in sporadic leukaemia, albeit infrequently. Hypermethylation was found to result in hypersensitivity towards DNA cross-linking agents, a hallmark of the FA cellular phenotype, suggesting that these samples displayed chromosomal instability. This instability may have contributed to the occurrence of the leukaemia. In addition, this is the first report to describe hypermethylation of FANCC and FANCL. This warrants the investigation of multiple FA-BRCA genes in other malignancies.